It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker.

In this comprehensive Journal of Clinical Oncology clinical review, the authors suggest that reexamination of breast cancer risk reduction strategies and clinical practice is needed. Prediction models, breast cancer mortality, prognostic categories, and the Women’s Health Initiative (WHI) randomized trials, dietary modification (DM) trial, hormone therapy trials, estrogen, and estrogen plus progestin trials are all discussed in great detail.

Key Points: In two study cohorts, less-intensive therapies increased mortality in each of three risk groups defined by age, comorbidities, and cytogenetics. The differences became nonsignificant after accounting for physician perception of cure, emphasizing the need for a randomized trial.Design: Multicenter retrospective cohort (1,292), 6 institutions, 2008-2012; prospective cohort (695), 13 institutions, 2013 – 2017Connected Content: Fitness for Intensive Chemotherapy: A Continuing Conundrum

The investigational agent – known as REGEN-COV (casirivimab and imdevimab) – was previously granted the Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19. Now, those who are at high risk for progression to severe COVID-19, including hospitalization or death, have an option.

Is the debate over? The Morbidity and Mortality Weekly Report (MMWR) discusses this case-control study, which showed that people are twice as likely to get infected again if they are unvaccinated. The debate over vaccinations has been bitter so far, but the results present comforting news for those vaccinated but worried about the fast-spreading Delta variant…while alerting the unvaccinated of their much higher potential to become infected again.

After diagnosis during a partial mastectomy, this patient’s estimated blood loss was 58 mL, causing anemia and requiring a red blood cell transfusion along with ventriculoperitoneal drain placement. With a substantive bleeding history before the diagnosis, what would you do next with this patient? Work her up for von Willebrand disease? Do a complete blood count test to look at platelet count, a peripheral smear to look at the morphology of the platelets, and a coagulation profile? Offer genetic testing for fibrinogen disorders? What would your next steps be? Read the full case presentation and expert opinion to see how your peers responded.